Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

[124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors.

Hall LT, Titz B, Baidya N, van der Kolk AG, Robins HI, Otto M, Perlman SB, Weichert JP, Kuo JS.

Mol Imaging Biol. 2019 Jun 10. doi: 10.1007/s11307-019-01362-1. [Epub ahead of print]

PMID:
31183841
2.

In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predicts Partitioning and Pharmacokinetics.

Zhang RR, Grudzinksi JJ, Mehta TI, Burnette RR, Hernandez R, Clark PA, Lubin JA, Pinchuk AN, Jeffrey J, Longino M, Kuo JS, Weichert JP.

Mol Pharm. 2019 Jul 8. doi: 10.1021/acs.molpharmaceut.8b01301. [Epub ahead of print]

PMID:
31082240
3.

Preclinical Characterization of 86/90Y-NM600 in a variety of murine and human cancer tumor models.

Grudzinski JJ, Hernandez R, Marsh I, Patel R, Aluicio-Sarduy E, Engle J, Morris Z, Bednarz B, Weichert JP.

J Nucl Med. 2019 Apr 6. pii: jnumed.118.224808. doi: 10.2967/jnumed.118.224808. [Epub ahead of print]

PMID:
30954941
4.

Preclinical pharmacokinetics and dosimetry studies of [124I/131I]-CLR1404 for treatment of pediatric solid tumors in murine xenograft models.

Marsh IR, Grudzinski JJ, Baiu DC, Besemer AE, Hernandez R, Jeffery JJ, Weichert JP, Otto M, Bednarz BP.

J Nucl Med. 2019 Mar 29. pii: jnumed.118.225409. doi: 10.2967/jnumed.118.225409. [Epub ahead of print]

PMID:
30926646
5.

90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP.

Commun Biol. 2019 Feb 26;2:79. doi: 10.1038/s42003-019-0327-4. eCollection 2019.

6.

Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Besemer AE, Grudzinski JJ, Weichert JP, Hall LT, Bednarz BP.

Cancer Biother Radiopharm. 2019 Feb;34(1):13-23. doi: 10.1089/cbr.2018.2568. Epub 2018 Oct 23.

PMID:
30351218
7.

Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog.

Elsaid MY, Shahi A, Wang AR, Baiu DC, Li C, Werner LR, Singhal S, Hall LT, Weichert JP, Armstrong EA, Bednarz BP, Harari PM, Iyer G, Otto M.

Mol Cancer Ther. 2018 Nov;17(11):2320-2328. doi: 10.1158/1535-7163.MCT-17-0897. Epub 2018 Aug 14.

PMID:
30108133
8.

PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors.

Hall LT, Titz B, Robins HI, Bednarz BP, Perlman SB, Weichert JP, Kuo JS.

Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):157-166. eCollection 2017.

9.

Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.

Baiu DC, Marsh IR, Boruch AE, Shahi A, Bhattacharya S, Jeffery JJ, Zhao Q, Hall LT, Weichert JP, Bednarz BP, Otto M.

J Nucl Med. 2018 Feb;59(2):244-250. doi: 10.2967/jnumed.117.193748. Epub 2017 Jul 26.

10.

Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404.

Besemer AE, Titz B, Grudzinski JJ, Weichert JP, Kuo JS, Robins HI, Hall LT, Bednarz BP.

Phys Med Biol. 2017 Jul 6;62(15):6008-6025. doi: 10.1088/1361-6560/aa716d.

PMID:
28682793
11.

Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection.

Tummers WS, Warram JM, Tipirneni KE, Fengler J, Jacobs P, Shankar L, Henderson L, Ballard B, Pfefer TJ, Pogue BW, Weichert JP, Bouvet M, Sorger J, Contag CH, Frangioni JV, Tweedle MF, Basilion JP, Gambhir SS, Rosenthal EL.

Cancer Res. 2017 May 1;77(9):2197-2206. doi: 10.1158/0008-5472.CAN-16-3217. Epub 2017 Apr 20. Erratum in: Cancer Res. 2018 Feb 15;78(4):1123.

12.

Beyond the margins: real-time detection of cancer using targeted fluorophores.

Zhang RR, Schroeder AB, Grudzinski JJ, Rosenthal EL, Warram JM, Pinchuk AN, Eliceiri KW, Kuo JS, Weichert JP.

Nat Rev Clin Oncol. 2017 Jun;14(6):347-364. doi: 10.1038/nrclinonc.2016.212. Epub 2017 Jan 17. Review.

13.

Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.

Zhang RR, Swanson KI, Hall LT, Weichert JP, Kuo JS.

CNS Oncol. 2016 Oct;5(4):223-31. doi: 10.2217/cns-2016-0017. Epub 2016 Sep 12.

14.

Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model.

Clark PA, Al-Ahmad AJ, Qian T, Zhang RR, Wilson HK, Weichert JP, Palecek SP, Kuo JS, Shusta EV.

Mol Pharm. 2016 Sep 6;13(9):3341-9. doi: 10.1021/acs.molpharmaceut.6b00441. Epub 2016 Aug 4.

15.

Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma.

Marino R, Baiu DC, Bhattacharya S, Titz B, Hebron E, Menapace BD, Singhal S, Eickhoff JC, Asimakopoulos F, Weichert JP, Otto M.

Am J Cancer Res. 2015 Oct 15;5(11):3422-35. eCollection 2015.

16.

Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report.

Rosenthal EL, Warram JM, de Boer E, Basilion JP, Biel MA, Bogyo M, Bouvet M, Brigman BE, Colson YL, DeMeester SR, Gurtner GC, Ishizawa T, Jacobs PM, Keereweer S, Liao JC, Nguyen QT, Olson JM, Paulsen KD, Rieves D, Sumer BD, Tweedle MF, Vahrmeijer AL, Weichert JP, Wilson BC, Zenn MR, Zinn KR, van Dam GM.

J Nucl Med. 2016 Jan;57(1):144-50. doi: 10.2967/jnumed.115.158915. Epub 2015 Oct 8.

17.

Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems.

Morris ZS, Weichert JP, Saker J, Armstrong EA, Besemer A, Bednarz B, Kimple RJ, Harari PM.

Radiother Oncol. 2015 Sep;116(3):504-9. doi: 10.1016/j.radonc.2015.06.015. Epub 2015 Jun 26.

18.

Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.

Swanson KI, Clark PA, Zhang RR, Kandela IK, Farhoud M, Weichert JP, Kuo JS.

Neurosurgery. 2015 Feb;76(2):115-23; discussion 123-4. doi: 10.1227/NEU.0000000000000622.

19.

A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.

Grudzinski JJ, Titz B, Kozak K, Clarke W, Allen E, Trembath L, Stabin M, Marshall J, Cho SY, Wong TZ, Mortimer J, Weichert JP.

PLoS One. 2014 Nov 17;9(11):e111652. doi: 10.1371/journal.pone.0111652. eCollection 2014.

20.

Phospholipid ether analogs for the detection of colorectal tumors.

Deming DA, Maher ME, Leystra AA, Grudzinski JP, Clipson L, Albrecht DM, Washington MK, Matkowskyj KA, Hall LT, Lubner SJ, Weichert JP, Halberg RB.

PLoS One. 2014 Oct 6;9(10):e109668. doi: 10.1371/journal.pone.0109668. eCollection 2014.

21.

Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, Pazoles CJ, Pickhardt PJ, Kuo JS.

Sci Transl Med. 2014 Jun 11;6(240):240ra75. doi: 10.1126/scitranslmed.3007646.

22.

mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.

Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, Halberg RB.

PLoS One. 2013 Apr 9;8(4):e60709. doi: 10.1371/journal.pone.0060709. Print 2013.

23.

Improved kinetic analysis of dynamic PET data with optimized HYPR-LR.

Floberg JM, Mistretta CA, Weichert JP, Hall LT, Holden JE, Christian BT.

Med Phys. 2012 Jun;39(6):3319-31. doi: 10.1118/1.4718669.

24.

Mice expressing activated PI3K rapidly develop advanced colon cancer.

Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan R, Washington MK, Torrealba JR, Weichert JP, Halberg RB.

Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23.

25.

Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT.

Grudzinski JJ, Floberg JM, Mudd SR, Jeffery JJ, Peterson ET, Nomura A, Burnette RR, Tomé WA, Weichert JP, Jeraj R.

Phys Med Biol. 2012 Mar 21;57(6):1641-57. doi: 10.1088/0031-9155/57/6/1641. Epub 2012 Mar 7.

26.

Positron emission tomography assessment of 8-OH-DPAT-mediated changes in an index of cerebral glucose metabolism in female marmosets.

Converse AK, Aubert Y, Farhoud M, Weichert JP, Rowland IJ, Ingrisano NM, Allers KA, Sommer B, Abbott DH.

Neuroimage. 2012 Mar;60(1):447-55. doi: 10.1016/j.neuroimage.2011.12.065. Epub 2012 Jan 2.

27.

The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.

Grudzinski JJ, Tomé W, Weichert JP, Jeraj R.

Phys Med Biol. 2010 Oct 7;55(19):5723-34. doi: 10.1088/0031-9155/55/19/007. Epub 2010 Sep 8.

28.

Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.

Grudzinski JJ, Burnette RR, Weichert JP, Jeraj R.

Cancer Biother Radiopharm. 2010 Aug;25(4):417-26. doi: 10.1089/cbr.2009.0754.

29.

Hybrid PET/CT for noninvasive pharmacokinetic evaluation of dynamic PolyConjugates, a synthetic siRNA delivery system.

Mudd SR, Trubetskoy VS, Blokhin AV, Weichert JP, Wolff JA.

Bioconjug Chem. 2010 Jul 21;21(7):1183-9. doi: 10.1021/bc900558z.

PMID:
20552976
30.

Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection.

Jiang H, Cannon MJ, Banach M, Pinchuk AN, Ton GN, Scheuerell C, Longino MA, Weichert JP, Tollefson R, Clarke WR, Ji QC, Jiang X.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1513-8. doi: 10.1016/j.jchromb.2010.04.002. Epub 2010 Apr 10.

PMID:
20434411
31.

Longitudinal assessment of colonic tumor fate in mice by computed tomography and optical colonoscopy.

Durkee BY, Shinki K, Newton MA, Iverson CE, Weichert JP, Dove WF, Halberg RB.

Acad Radiol. 2009 Dec;16(12):1475-82. doi: 10.1016/j.acra.2009.07.023.

32.

Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation.

Grudzinski JJ, Yoriyaz H, Deluca PM Jr, Weichert JP.

Appl Radiat Isot. 2010 Jan;68(1):59-65. doi: 10.1016/j.apradiso.2009.09.070. Epub 2009 Oct 13.

PMID:
19879154
33.

Small animal micro-CT colonography.

Durkee BY, Weichert JP, Halberg RB.

Methods. 2010 Jan;50(1):36-41. doi: 10.1016/j.ymeth.2009.07.008. Epub 2009 Aug 3.

34.

Reproducibility of tumor volume measurement at microCT colonography in living mice.

Durkee BY, Mudd SR, Roen CN, Clipson L, Newton MA, Weichert JP, Pickhardt PJ, Halberg RB.

Acad Radiol. 2008 Mar;15(3):334-41. doi: 10.1016/j.acra.2007.10.005.

35.

Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues.

Pinchuk AN, Rampy MA, Longino MA, Skinner RW, Gross MD, Weichert JP, Counsell RE.

J Med Chem. 2006 Apr 6;49(7):2155-65.

PMID:
16570911
36.

Low-attenuation oral GI contrast agents in abdominal-pelvic computed tomography.

Hebert JJ, Taylor AJ, Winter TC, Reichelderfer M, Weichert JP.

Abdom Imaging. 2006 Jan-Feb;31(1):48-53.

PMID:
16252139
37.

Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: part II: pharmacokinetics and biodistribution in normal and tumor-bearing rodents.

Ton GN, Weichert JP, Longino MA, Fine JP, Kwon GS.

J Control Release. 2005 May 5;104(1):155-66. Epub 2005 Mar 29.

PMID:
15866342
38.

Microcomputed tomography colonography for polyp detection in an in vivo mouse tumor model.

Pickhardt PJ, Halberg RB, Taylor AJ, Durkee BY, Fine J, Lee FT Jr, Weichert JP.

Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3419-22. Epub 2005 Feb 22.

39.

Imaging of murine liver tumor using microCT with a hepatocyte-selective contrast agent: accuracy is dependent on adequate contrast enhancement.

Weber SM, Peterson KA, Durkee B, Qi C, Longino M, Warner T, Lee FT Jr, Weichert JP.

J Surg Res. 2004 Jun 1;119(1):41-5.

PMID:
15126080
40.

Imaging efficacy of a hepatocyte-selective polyiodinated triglyceride (DHOG-LE) for contrast-enhanced CT.

Doerr-Stevens JK, Bakan DA, Lee FT Jr, Chosy SG, Markhardt BK, Bonneville AK, Burrascano C, Delaney C, Longino MA, Greener Y, Weichert JP.

Acad Radiol. 2002 May;9 Suppl 1:S200-4. No abstract available.

PMID:
12019869
41.

Hepatobiliary imaging using a novel hepatocyte-selective CT contrast agent.

Bakan DA, Lee FT Jr, Weichert JP, Longino MA, Counsell RE.

Acad Radiol. 2002 May;9 Suppl 1:S194-9. No abstract available.

PMID:
12019866
42.

Percutaneous CT lymphography using a new polyiodinated biomimetic microemulsion.

Wisner ER, Weichert JP, Longino MA, Counsell RE, Weisbrode SE.

Acad Radiol. 2002 May;9 Suppl 1:S191-3. No abstract available.

PMID:
12019865
43.

A surface-modified chylomicron remnant-like emulsion for percutaneous computed tomography lymphography: synthesis and preliminary imaging findings.

Wisner ER, Weichert JP, Longino MA, Counsell RE, Weisbrode SE.

Invest Radiol. 2002 Apr;37(4):232-9.

PMID:
11923646
44.

Imaging efficacy of a hepatocyte-selective polyiodinated triglyceride for contrast-enhanced computed tomography.

Bakan DA, Doerr-Stevens JK, Weichert JP, Longino MA, Lee FT Jr, Counsell RE.

Am J Ther. 2001 Sep-Oct;8(5):359-65.

PMID:
11550077
45.

Combined hepatocyte-selective and blood-pool contrast agents for the CT detection of experimental liver tumors in rabbits.

Weichert JP, Lee FT Jr, Chosy SG, Longino MA, Kuhlman JE, Heisey DM, Leverson GE.

Radiology. 2000 Sep;216(3):865-71.

PMID:
10966724
47.

Lipid-based blood-pool CT imaging of the liver.

Weichert JP, Lee FT Jr, Longino MA, Chosy SG, Counsell RE.

Acad Radiol. 1998 Apr;5 Suppl 1:S16-9; discussion S28-30.

PMID:
9561034
48.

CT depiction of experimental liver tumors: contrast enhancement with hepatocyte-selective iodinated triglyceride versus conventional techniques.

Lee FT Jr, Chosy SG, Naidu SG, Goldfarb S, Weichert JP, Bakan DA, Kuhlman JE, Tambeaux RH, Sproat IA.

Radiology. 1997 May;203(2):465-70. Erratum in: Radiology 1997 Aug;204(2):338.

PMID:
9114106
50.

Biological disposition and imaging of a radioiodinated alkylphosphocholine in two rodent models of breast cancer.

Rampy MA, Brown RS, Pinchuk AN, Weichert JP, Skinner RW, Fisher SJ, Wahl RL, Gross MD, Ethier SP, Counsell RE.

J Nucl Med. 1996 Sep;37(9):1540-5.

Supplemental Content

Loading ...
Support Center